The gold standard laboratory tests used to diagnose invasive Candida infection (ICI) are based on the in vitro culture of blood or samples from other sterile sites. However, these tests have limited sensitivity (Se) and are generally not diagnostic until late in the infectious process. The Serion Candida mannan kit was evaluated for the diagnosis of ICI at Grenoble University Hospital (France) between 2007 and 2011. The results were then compared with worldwide data published between 1997 and 2011. This retrospective study was based on follow-up from the investigation of 162 patients of whom 91 had proven ICI; 13 had Candida colonization index (CCI) scores ≥0.42, positive mannan tests, with nonconcomitant infections; and 58 had no evidence of Candida infection. Candida albicans, C. glabrata, C. tropicalis, and C. parapsilosis were the etiologic agents in 104 patients. For patients with or without ICI, the 12-week mortality rates were 35/104 (33.7%) and 6/58 (10.3%), respectively. The mannan diagnostic specificity was 51% and Se was 77%. However, in the metaanalysis (n = 1,536), values were 86% and 62%, respectively. Positive mannan test results may appear early (median 6 days) in the development of candidemia and have moderate diagnostic value for ICI, with a negative predictive value of 83%. In patients at risk of ICI with negative candidemia, the combination of Candida mannan test data with a CCI score ≥0.42 may improve the diagnosis of probable ICI.
Introduction
Invasive fungal diseases (IFDs) are usually observed in patients who are immunocompromised and have hematological malignancies, have undergone transplant procedures, and/or have solid tumors. IFDs have also been noted in critically ill, nonimmunosuppressed patients who have had major gastrointestinal or heart surgery [1] . Such infections are usually associated with high mortality. For instance, in North America between 2004 and 2008, the mortality rates for invasive Candida infection (ICI) varied from 37.5% to 75.0% [2] . ICI is also related to significant morbidity as a result of relatively long stays in intensive care units, ranging from 1 to several weeks [3] . Furthermore, the incidence of systemic infections due to Candida spp. has increased in hospitals worldwide [3] . Since clinical signs and symptoms are not specific, therapy with preventative broad-spectrum antibacterial drugs is initiated empirically; if fever persists, an antifungal drug should be administered. In other patients with high-risk factors, antifungal therapy is administered at the start of the hospital stay. The laboratory diagnosis of ICI is mainly based on cultures of blood and samples from other sterile sites. However, both tests may have limited sensitivity (Se), with delays in the development of positive results [4] . A fungal-negative culture may be considered to be inconclusive in certain patients receiving antifungal therapy. Nonculture-based tests, including serology and molecular biology assays, have been developed in order to decrease the incidence of inconclusive results from this phenotypic test [4] [5] [6] [7] [8] [9] [10] . Information on circulating biomarkers, such as Candida albicans mannan and/or (1→3)-β-D-glucan, may be obtained prior to receipt of the results of culture-based tests, thus allowing early initiation of adequate antifungal therapy and, in turn, improvement in patient outcomes [11] [12] [13] . Mannans, which are involved in innate and acquired immunity, are a main cell wall component of Candida spp. and are used as biomarkers [14] [15] [16] . The detection of Candida mannans in a cutaneous biopsy confirmed disseminated candidiasis due to C. albicans in a patient with aplastic anemia and candidemia [16] . While tests for the Candida mannan antigen that use mainly monoclonal antibodies have been well assessed in the literature [17] [18] [19] , the Serion kit (Serion GmbH; Institute Virion, Wurzburg, Germany), which uses polyclonal antibodies to obtain quantified data, has been evaluated only once [5, 17] . The present case-control study was based on common practice at Grenoble University Hospital (France). We hypothesized that the subgroup of patients with negative candidemia, a Candida colonization index (CCI) score ≥0.42, a positive mannan test, and no other concomitant infections may have probable ICI [20] . This study did not have any epidemiological purpose. The test results were compared with proven and probable ICI results before being integrated into a metaanalysis with data from published studies.
Materials and methods

Sampling and laboratory tests
Clinicians independently prescribed the laboratory analysis and number of sites examined. Biological samples (blood, biopsy, bronchoalveolar lavage fluid, tracheal aspirates, urine) were cultured for fungal detection using the European Community-labeled mycosis IC/F medium (Bactec Mycosis IC/F, Becton Dickinson Diagnostic Systems, Sparks, MD, USA) [21, 22] . A CCI score was calculated for each patient; stool/rectal swabs were included. Neutrophil and lymphocyte counts and C-reactive protein (CRP) levels were determined. The Serion mannan assay was performed twice, 1 week apart; the initial assay with the fresh serum and the second with the respective serum that had been immediately stored at −20
• C after centrifugation of the initial blood samples. The Serion enzyme-linked immunosorbent assay antigen Candida kit was used for detection of Candida mannan antigen according to the procedure recommended by both the manufacturer and Lunel et al. [5] . Briefly, the kit uses microtiter wells coated with polyclonal antibodies against C. albicans mannans. Every test had blank assays as well as positive and negative controls. The 300-μl serum samples were diluted with 100 μl of sample buffer and incubated at 110
• C for 5 min followed by centrifugation at 9000 g for 10 min. The resultant clear supernatant was used for the assay (see manufacturer instructions). A standard curve was plotted to convert the absorbency values into Candida mannan levels, expressed in arbitrary units (U) per milliliter. Per the manufacturer's recommendations, the detection was considered significant when the level was ≥2.30 U/ml.
Patient and control groups
Patients who presented with at least four risk factors associated with the development of IFD were included in this retrospective case-control study [3] . The risk factors included premature low-birthweight infants; patients receiving broad-spectrum antibiotics or cancer therapy; and patients with immunosuppression, neutropenia, colonization of several body sites that include candiduria of ≥10 Table 1 ) [20] .
Statistical analysis of study location
Significant differences between the two groups were determined using the Mann-Whitney U test. The mannan levels obtained at a one-week interval were analyzed using the paired t test. A P value ≤0.05 was considered to be statistically significant. Pearson χ 2 test was used for analysis of Candida mannan and/or colonization prevalence. A receiving operating characteristic (ROC) curve was plotted, and the area under the curve (AUC) was calculated in order to estimate the discriminatory power of the Candida mannan assay between infected and uninfected patients.
Metaanalysis
To synthesize and quantitatively compare our data with that published worldwide between 1999 and 2011, a hierarchical summary ROC (SROC) curve was drawn. These data were identified using a Medline search for Candida mannan, in which at least the Se and specificity (Sp) of the diagnostic test used were provided [5,6,9- 
Results
Local study
The demographic, clinical, hematological, biochemical, and mycological characteristics as well as some of the high-risk factors for ICI of the patients enrolled in our study are shown in Table 1 . The laboratory follow-up per patient was from 1 to 124 days, with a median of 29 days. From one to five body sites were tested for Candida colonization, with a median of two sites per patient. The frequency of mycological laboratory examination was from 1 to 10 days (median, 4 days). In total, 173/181 (95.6%; 95% CI, 91.5-97.7) species isolated in this study were members of the Candida genus ( To optimize the conditions of use of the Serion Candida mannan kit, two quantification tests were performed, one from fresh serum and one from a 1-week-old frozen serum sample (Fig. 1) . The first series (median = 2.57 U/ml) showed significantly higher mannan quantities than the second (median = 1.68 U/ml; n = 72; paired t test; P < 0.001), suggesting the metabolic degradation or instability of mannan in serum. Therefore, only the results of the first quantification were used in the present investigation. In the local study, serum mannan prevalence was 76.3% (29/38; 95% CI, 61.6%-87.7%) in the group of patients with proven ICI (Table 1 ). In our retrospective local study, only 94/162 patients had mannan data.
The optimal mannan cutoff obtained from the ROC curve was 2.29 U/ml (Fig. 2a) . The difference in serum mannan levels for samples from which C. albicans (median, 2.3 U/ml; n = 37) was successfully recovered and samples that yielded non-C. albicans isolates was not statistically different (median, 2.8 U/ml; n = 71; Mann-Whitney U test, P = 0.218). The Candida mannan prevalence was higher in the group of patients colonized or infected by C. albicans, C. glabrata, and C. tropicalis than in the group of patients colonized or infected by C. parapsilosis, C. lusitaniae, C. kefyr, C. guilliermondii, C. pulcherrima, and C. inconspicua: 49% (30/61; 95% CI, 37-61%) vs. 39% (7/18; 95% CI, 20-61%), respectively. However, this was not statistically significant. In 11/21 (52.4%; 95% CI, 32.2%-71.8%) cases of positive candidemia, serum mannan content tests were positive prior to those that indicated candidemia (median 6 days). In 2/21 (9.5%; 95% CI, 2.9%-29.2%) cases of positive candidemia, serum mannan content was positive when candidemia tests were positive; in 8/21 (38.1%; 95% CI, 20.7%-59.3%), the serum mannan content was positive (median) 9 days after testing positive for candidemia. In the local study, the Se, Sp, and AUC of the Serion Candida mannan test were 77%, 51%, and 0.60, respectively (Fig. 2a) . The combination of a positive mannan test with Candida colonization significantly improved (Pearson χ 2 test: Q = 33.73, P < 0.0001) the diagnostic Sp of the mannan assay (Table 1 ; Pearson χ 2 test: Q = 7.45, P = 0.006).
Metaanalysis
Fourteen studies that covered 1536 patients met our search criteria. To precisely and visually compare our data with other published results, we used a SROC curve (Fig. 2b ) with confidence and prediction contours. The metaanalysis values were Se-SROC = 62% (95% CI, 52-72), Sp-SROC = 86% (95% CI, 76-93), and AUC-SROC = 0.79 (95% CI, 0.75-0.82). These values were calculated on the basis of mannan detection, the χ 2 test of homogeneity, and the inconsistency index for the studies and the kits used. Figure 2c shows the Deeks' funnel plot asymmetry test data for all studies analyzed. The slope of the regression line was significantly different from zero (P = 0.77 > 0.10), and the selected studies did not present any statistical publication bias. Table 3 shows the evaluation of Candida mannan tests for the diagnosis of ICI with the Se, Sp, positive predictive value, negative predictive value, efficiency, and Matthews correlation coefficient. The summary parameters, which are listed on the last line of Table 3 , were calculated conventionally, with the exception of Se-SROC and Sp-SROC, which were estimated as indicated above. The results of the diagnostic accuracy test are presented in Figure 3 in the form of a Forest plot in which the Se, Sp, DOR, and CIs of Candida mannan tests are given for our study and for studies selected from the literature. Concerning these four parameters, the heterogeneity of the results was evaluated graphically using the Forest plot and statistically using the inconsistency index values that were >50%: 74% for Se (95% CI, 61-87), 94% for Sp (95% CI, 92-96), and 99.98% for DOR. The mannan assays used monoclonal antibodies (Platelia, except New Platelia, which uses polyclonal The Candida fungal species, which were isolated from false-negative cases using the Serion kit, included C. albicans (n = 4), C. tropicalis (n = 3), C. glabrata (n = 4), and C. parapsilosis (n = 2 The sensitivity-summary receiving operating characteristic and specificity-summary receiving operating characteristic were obtained by taking into account the χ 2 test of the homogeneity and the inconsistency index (% of total variation) among the studies. c In general, the samples came from several wards. Only the most significant ones in terms of number of cases appear here.
antibodies; Cica fungi; and "in house"; data from Table 3) appear to have better Sp (86%; [795/(795+127)] × 100) than assays that use polyclonal (Serion) antibodies (58%, [59/(59+42)] × 100). This difference was statistically significant (Pearson χ 2 test: Q = 5.24, P = 0.022).
Discussion
The extent of ICI is very difficult to define within the context of IFD. We adapted the classification of patients with IFD from the description by De Pauw et al. [20] of patients with ICI. The notion of proven, probable, and possible IFD was indicated based on the following statement: "Cases of probable IFD require that a host factor, clinical features, and mycological evidence be present" [20] . Among the indicated mycological criteria are "indirect tests (detection of antigen or cell-wall constituents)" [20] . Therefore, it is justifiable to add detection of such constituents as a criterion in the definition of probable ICI cases. In the local study, serum mannan prevalence was 76.3% in the group of patients with proven ICI and thus may designate a probability of proven ICI. In the definition of probable ICI, we also introduced the concept of nonconcomitant infections because, in some cases, the detection of mannans may lack Sp. We improved the definition of the probability of occurrence of proven ICI by adding the CCI score. In the local study, the CCI prevalence among the cases of positive candidemia was 90.1%. Taking into account all of these arguments, we can assume that the subgroup formed in material and methods with the summarized characteristics had probable ICI. In the literature, the CCI threshold value varies from 0.4 to 0.5; in our local study, the threshold used for CCI was 0.42. Thus, the results of our local study suggest that a positive serum Candida mannan test associated with a positive Candida colonization increased the Sp of the laboratory diagnosis. ICI is a potentially fatal disease despite advances in hospital hygiene, therapeutics, and laboratory tests [1, 2, 9, 21, 24] . The 12-week mortality rates seen in our hospital corroborate these findings. However, our study was not built for epidemiological purposes as we included only patients at high risk of ICI and with at least one Candida mannan assay. Consequently, the number of patients in the control group was lower than in the invasive Candida group. This does not reflect the fact that ICI patients represent between one and eight of all patients admitted to hospitals [3] . At our hospital, testing for Candida mannan is not systematic, even for high-risk patients, which accounts for the relatively low number of patients in the control group. We made no attempt to analyze ICI incidence in terms of hospital wards, which would have required a larger study population. Also, we did not evaluate beta-glucans, another important cell wall component of Candida and other fungal species, as they are regarded as pan-fungal biomarkers [13, 31] .
In our laboratory assays, a significant decrease in mannan levels at 1-week intervals was found, although the serum samples were frozen for storage. Thus, only the first measurements obtained with fresh serum were analyzed in our study. The apparent requirement for fresh serum samples may be a disadvantage of the Serion kit. The lack of reproducibility of the assay between fresh and frozen serum suggests the degradation of mannan epitopes by soluble cytosolic mannosidase activity in C. albicans and humans [32, 33] . It is likely that the Serion test also lacks robustness. Together, these considerations may, in part, explain the differences in Se observed in both our study and our metaanalysis [17, 18, 24, 26, 27, 30] . However, the Se found in our hospital (77%) falls within the range (31%-100%) of Se values mentioned by Mikulska et al. (overall Se 62%) [17] . Our relatively good Se but only moderate Sp is in line with those of the other studies.
In contrast with earlier research, the studies selected for our metaanalysis did not show any publication bias for the 1536 patients included [17] . According to Mikulska et al., a known degree of heterogeneity has been observed [17] . Heterogeneity is indeed inherent to ICI for the following reasons: patients of all ages may be affected, from preterm infants to elderly patients; the high-risk factors for ICI can vary among patients and among treatments; different cutoff values are used in the different studies; a SROC curve provides information on the overall performance of the assay; and diverse Candida spp. that cause infection are involved in different parts of the world [1] . The Se of Candida mannan detection tests may vary depending on which infecting Candida spp. is present since each species has a unique mannan structure [14, 17] .
Furthermore, in our metaanalysis, mannan assays that used monoclonal antibodies (Platelia) may have provided more Sp than assays that used polyclonal (Serion) antibodies. A possible reason for the variations in Se levels of Candida mannan assays may be that the fact that the cell wall mannan of Candida spp. is species specific and the Candida mannan epitopes can involve alpha-1, 2-, alpha-1, 3-, alpha-1, 6-, and/or beta-1, 2-linked mannopyranose units [14] . Mikulska et al. noted that Candida spp. affected the mannan sensitivities, which may vary from 0% (C. krusei) to 100% (C. tropicalis) [17] . Another reason for these variations may be that the number of epitopes, the number of which is based on the phosphate-bound beta-1, 2-linked manno-oligosaccharides, may have fewer hyphal cells than yeast cells, as reflected in the results of Sendid et al. [28] . Finally, circulating Candida mannans bind mannose-binding lectin (MBL), as indirectly observed by the significant decrease in serum MBL levels during the 2 days preceding candidemia and/or mannanemia episodes in ICI patients [14, 34] . The cause of the moderate lack of Sp may be due to the Candida mannan antibodies used in the test. These antibodies cross-react with other mannans from other microorganisms such as Saccharomyces cerevisiae and Mycobacterium paratuberculosis [35] [36] [37] . The possibility of cross-reaction decreases in patients who do not have bacteremia or bacterial colonization but do who have a positive CCI score (≥0.42) obtained from different body sites. Thus, as seen in our study, positive Candida mannan detection should be combined with a CCI score (≥0.42) in order to improve diagnostic Sp.
Several researchers have suggested that positive Candida mannan detection be combined with an assay of antiCandida mannan antibodies in order to improve ICI diagnosis [11, 17, 27, 29] . Also, in this recommendation [17] , the presence of anti-mannan antibodies could improve the Sp of Candida mannan detection. Concentration of anti-mannan antibodies may increase after the mannanemia/blood culture period in ICI patients [34] . Immunocompromised patients have high-risk factors for ICI; thus, the measurements of Candida mannan levels may be useful when combined with low levels of serum anti-Candida antibodies, which is usually the case for these patients. However, no Candida spp. have been identified using only this approach; the result is a reduction in optimal therapeutic options. In this study, anti-mannan antibodies were not detected since antibodies to C. albicans wall antigens (indirect fluorescent antibody assays) and precipitins to C. albicans (immunoelectrophoresis) had been measured in our hospital (data not shown).
It is important to note that in patients with vulvovaginal candidiasis who do not usually present with a high risk for ICI, Candida mannan may also be detected on vaginal swabs and have Se values ranging from 80.3% to 98.6% [38, 39] . In contrast, the serum Se is only 20% (2/10) [18] . Yet, Mokaddas et al. found that none of their colonized patients had positive Candida mannan levels [19] . In patients at high risk for ICI without any other concomitant infection, our data and those from others may back up the argument that serum Candida mannan is a promising biomarker of probable ICI in combination with another specific one such as anti-mannan antibody [3, 17, 23] or CCI score >0.42.
While a sterile-site culture assay remains the gold standard [16] for ICI, a Candida mannan assay may be useful for detecting Candida mannan before a diagnosis of candidemia can be made. In our hospital, about 50% of analyzed cases had early positive results. The advantage of an early diagnosis was shown in five studies reviewed by Mikulska et al. [17] . Likewise, early detection can confirm probable ICI in cases with persistently negative candidemia and a positive CCI score. Moreover, the relatively high negative predictive value of the Candida mannan tests suggests that they are useful in screening patients at risk for ICI [27] .
Conclusion
Our study and the systematic review of the literature show that the different commercially available Candida mannan tests have moderate to relatively good Se and Sp in patients with ICI or candidemia [17] . In clinically suspected patients whose candidemia results remain negative, a Candida mannan assay could have an adjunctive role [6, 38, 39] in combination with a CCI score >0.42, providing a probable direct indication of active disease and reducing the possibility of false-positive results. In some cases, faster diagnosis may allow the patient's outcome to be improved thanks to earlier initiation of satisfactory antifungal therapy.
